RxDoctor Payments DataLook up a doctor →

Brandy Eason

Family · Little Rock, ARNPI 1548629199

Payments from drug & device makers

$12,588in general payments, 2019–2025

Across 756 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Enterra Medical, Inc.$526
  • Gilead$499
  • Ironwood Pharmaceuticals, Inc$464
  • plus $5K from 30 others

What the payments were for

  • Food & beverage$12,42299%
  • Education$1671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,588 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$14,613
Medicare patients
85
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase18$50,889
ZenpepLipase/Protease/Amylase12$34,177
LinzessLinaclotide30$23,027
MounjaroTirzepatide12$12,440
MovantikNaloxegol Oxalate13$5,193
Budesonide DrBudesonide12$1,246
Pantoprazole Sodium149$1,019
Famotidine84$680
Colestipol Hcl12$510
Omeprazole47$486
Lactulose14$351
Metoclopramide Hcl30$143
Nortriptyline Hcl15$69
Promethazine Hcl11$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$4,038$73,91548 claims
Aimmune Therapeutics, Inc.Zenpep$464$34,17712 claims
Lilly USA, LLCMounjaro$176$12,44012 claims
Redhill Biopharma Inc.Movantik$56$5,19313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.

Other family in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →